249 related articles for article (PubMed ID: 28524709)
1. Pharmacokinetics of ingenol mebutate gel under maximum use conditions in large treatment areas.
Bucko AD; Jarratt M; Stough DB; Kyhl L; Villumsen J; Hall A
J Dermatolog Treat; 2018 Feb; 29(1):74-79. PubMed ID: 28524709
[TBL] [Abstract][Full Text] [Related]
2. Ingenol mebutate gel for actinic keratosis.
Lebwohl M; Swanson N; Anderson LL; Melgaard A; Xu Z; Berman B
N Engl J Med; 2012 Mar; 366(11):1010-9. PubMed ID: 22417254
[TBL] [Abstract][Full Text] [Related]
3. A dose-finding trial with a novel ingenol derivative (ingenol disoxate: LEO 43204) for field treatment of actinic keratosis on full face or 250 cm
Bourcier M; Stein Gold L; Guenther L; Andreassen CM; Selmer J; Goldenberg G
J Dermatolog Treat; 2017 Nov; 28(7):652-658. PubMed ID: 28264612
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Safety of Ingenol Disoxate Gel Administered Under Maximum-Use Conditions to Patients With Actinic Keratosis.
Lain E; Skov T; Hall A
Clin Drug Investig; 2018 Mar; 38(3):249-257. PubMed ID: 29204958
[TBL] [Abstract][Full Text] [Related]
5. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.
Siller G; Gebauer K; Welburn P; Katsamas J; Ogbourne SM
Australas J Dermatol; 2009 Feb; 50(1):16-22. PubMed ID: 19178487
[TBL] [Abstract][Full Text] [Related]
6. Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice.
Bettencourt MS
J Drugs Dermatol; 2014 Mar; 13(3):269-73. PubMed ID: 24595570
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses.
Lebwohl M; Shumack S; Stein Gold L; Melgaard A; Larsson T; Tyring SK
JAMA Dermatol; 2013 Jun; 149(6):666-70. PubMed ID: 23553119
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Efficacy and Irritation of Ingenol Mebutate Gel 0.015% Used With or Without Dimethicone Lotion for Treatment of Actinic Keratosis on the Face.
Jim On SC; Hashim PW; Nia JK; Lebwohl MG
J Drugs Dermatol; 2017 May; 16(5):432-436. PubMed ID: 28628678
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results.
Berman B; Goldenberg G; Hanke CW; Tyring SK; Werschler WP; Knudsen KM; Larsson T; Swanson N
J Drugs Dermatol; 2014 Jun; 13(6):741-7. PubMed ID: 24918567
[TBL] [Abstract][Full Text] [Related]
10. Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis.
Keating GM
Drugs; 2012 Dec; 72(18):2397-405. PubMed ID: 23231025
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive monitoring of subclinical and clinical actinic keratosis of face and scalp under topical treatment with ingenol mebutate gel 150 mcg/g by means of reflectance confocal microscopy and optical coherence tomography: New perspectives and comparison of diagnostic techniques.
Ruini C; Hartmann D; Bastian M; Ruzicka T; French LE; Berking C; von Braunmühl T
J Biophotonics; 2019 Jul; 12(7):e201800391. PubMed ID: 30653833
[TBL] [Abstract][Full Text] [Related]
12. Exploring the use of ingenol mebutate to prevent non-melanoma skin cancer.
Erlendsson AM
Dan Med J; 2017 Nov; 64(11):. PubMed ID: 29115209
[TBL] [Abstract][Full Text] [Related]
13. Treatment of actinic keratoses and cancerization field of the face and scalp with 0.015% ingenol mebutate gel in Brazilian individuals: safety, tolerability and patients' perspectives.
Gameiro L; Tovo LFR; Sanches Júnior JA; Aprahamian I
An Bras Dermatol; 2019 Jul; 94(3):313-319. PubMed ID: 31365660
[TBL] [Abstract][Full Text] [Related]
14. Treatment of facial actinic keratoses with aminolevulinic acid photodynamic therapy (ALA-PDT) or ingenol mebutate 0.015% gel with and without prior treatment with ALA-PDT.
Berman B; Nestor MS; Newburger J; Park H; Swenson N
J Drugs Dermatol; 2014 Nov; 13(11):1353-6. PubMed ID: 25607702
[TBL] [Abstract][Full Text] [Related]
15. Real-life efficacy and safety of ingenol mebutate for the treatment of actinic keratosis of the face and scalp: A single arm retrospective study.
Ricci F; Tambone S; Neri L; Fania L; Piccioni A; Guerriero C; Fargnoli MC; Peris K
J Dermatolog Treat; 2016 Nov; 27(6):525-530. PubMed ID: 27043050
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial comparing simultaneous vs. sequential field treatment of actinic keratosis with ingenol mebutate on two separate areas of the head and body.
Pellacani G; Peris K; Guillen C; Clonier F; Larsson T; Venkata R; Puig S
J Eur Acad Dermatol Venereol; 2015 Nov; 29(11):2192-8. PubMed ID: 26300464
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results.
Berman B; Goldenberg G; Hanke CW; Tyring SK; Werschler WP; Knudsen KM; Goncalves J; Larsson T; Skov T; Swanson N
J Drugs Dermatol; 2014 Feb; 13(2):154-60. PubMed ID: 24509965
[TBL] [Abstract][Full Text] [Related]
18. A randomized, phase IIa exploratory trial to assess the safety and preliminary efficacy of LEO 43204 in patients with actinic keratosis.
Sinnya S; Tan JM; Prow TW; Primiero C; McEniery E; Selmer J; Østerdal ML; Soyer HP
Br J Dermatol; 2016 Feb; 174(2):305-11. PubMed ID: 26499175
[TBL] [Abstract][Full Text] [Related]
19. Reduced degree of irritation during a second cycle of ingenol mebutate gel 0.015% for the treatment of actinic keratosis.
Jim On SC; Haddican M; Yaroshinsky A; Singer G; Lebwohl M
Cutis; 2015 Jan; 95(1):47-51. PubMed ID: 25671445
[TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.
Anderson L; Schmieder GJ; Werschler WP; Tschen EH; Ling MR; Stough DB; Katsamas J
J Am Acad Dermatol; 2009 Jun; 60(6):934-43. PubMed ID: 19467365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]